Replies to post #125930 on Biotech Values

[mcbio]

The manufacturer of a branded drug doesn’t need a partner to make and sell an authorized generic; all they have to do is change the packaging. In the case of Enbrel, if MNTA (or, less likely, some other company) obtained FDA approval for a substitutable Enbrel FoB, AMGN/PFE could launch an AG without any assistance from a third party.

If MNTA were to ink a comprehensive FoB deal with PFE, do you see any chance of MNTA being able to carve out rights to partner a substitutable Enbrel FoB with another party?